NEUK203-13NEUK203-13 Injection Safety, Tolerability, and Efficacy in Patients with Neuroendocrine Tumors

This study explores the safety and effectiveness of NEUK203-13 Injection in patients with Neuroendocrine Tumors who have not responded to standard systemic therapy. NEUK203-13 Injection is a type of cell therapy that targets a specific protein, Delta-like Protein 3 (DLL3), found on cancer cells. It is designed to recognize and eliminate these cells. The study is important as it aims to provide a new treatment option for patients who have not benefited from existing therapies, potentially improving their care and addressing unmet needs in the treatment of Neuroendocrine Tumors. During the study, participants will receive the NEUK203-13 Injection. The study measures the results by monitoring and recording any side effects or adverse events. The primary goal is to evaluate the safety of the treatment. This includes assessing the severity, duration, and relationship of any adverse events to the treatment. The study also aims to get a preliminary understanding of how well the treatment works in these patients.